Compare EPR Properties (EPR) vs Tango Therapeutics Inc. (TNGX) Price & Performance

EPR Properties (EPR) trades at $54.80, down 1.1% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The REIT shows strong profitability with a 91.41% gross margin and 37.66% net income margin, though net income dipped slightly in 2026. Recent news highlights its 6.5% dividend yield and focus on diversification beyond theaters into experiential properties, with Q3 2026 earnings due October 29, 2026.

The outlook is mixed: analyst consensus is a Buy with a $65.50 price target, implying ~20% upside, supported by a high yield and undervalued P/FFO. Risks include exposure to leisure and entertainment tenants, rising interest rates impacting financing costs, and the Q1 2026 earnings miss. Cash flow trends show a net outflow in 2026, warranting monitoring of dividend coverage.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.